First MAb approved for treatment of metastatic breast cancer.

T. L. Brenner, V. R. Adams

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations
Original languageEnglish
Pages (from-to)236-238
Number of pages3
JournalJournal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Volume39
Issue number2
DOIs
StatePublished - 1999

Bibliographical note

Funding Information:
is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Funding

is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

FundersFunder number
Ameri can Pharmaceutical Asso ciation

    ASJC Scopus subject areas

    • Pharmaceutical Science

    Fingerprint

    Dive into the research topics of 'First MAb approved for treatment of metastatic breast cancer.'. Together they form a unique fingerprint.

    Cite this